Business
Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management
Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, July 21, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released a comparative analysis detailing how its SofPulse® medical device out-performed all pharmaceutical competitors non-opioid alternatives for surgical pain management. Competitive post-operative pain management products compared and analyzed against Endonovo’s SofPulse® PEMF (Pulsed Electro-Magnetic Frequency) were: Pacira BioSciences, Inc. (PCRX) analgesic injectable Exparel®, Avanos Medical, Inc. (AVNS) Pain Pump On-Q® and Mallinckrodt plc (MNKPF) intravenous injection Ofirmev®. Endonovo’s comparative analysis detailed how SofPulse® has shown through clinical trials and surgical use to reduce opioid use and to directly replace injectable Exparel®, On-Q® pain pumps, Ofirmev® for patients in managing pain and/or edema post-operatively. Endonovo’s comparative analysis identified that Exparel®; On-Q®; and Ofirmev® are FDA cleared and indicated to reduce post-operative pain. None of these pharmaceutical pain management products analyzed are FDA cleared to reduce edema, which is blood swelling in post-operative wounds. Only SofPulse® is FDA cleared to reduce both pain and edema post-operatively. Additionally, the pharmaceutical pain management products analyzed are considered medically invasive requiring injections and/or catheter placement with numerous negative medical contraindications limiting their use. After 14 years of surgical use, SofPulse® in comparison to these pharmaceutical pain options is a superior alternative non-opioid, non-invasive, portable device with no contraindications and no known side effects. “Results of our product and medical results comparison analysis showed that SofPulse® outperformed Exparel®, On-Q® pain pumps and Ofirmev® in non-opioid post-operative pain management. The benefits of SofPulse® treatments without the use of narcotics or opioids were more effective than our competitors’ products which helps to set it significantly above our main competitors non-opioid post-operative pain management solution,” according to Endonovo CEO Alan Collier. There is high demand for opioid and narcotic substitutes for pain reduction in medical surgical cases. Patients’ overu...